Skip to main content
Journal cover image

Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ.

Publication ,  Journal Article
Worni, M; Akushevich, I; Greenup, R; Sarma, D; Ryser, MD; Myers, ER; Hwang, ES
Published in: J Natl Cancer Inst
December 2015

BACKGROUND: Impact of contemporary treatment of pre-invasive breast cancer (ductal carcinoma in situ [DCIS]) on long-term outcomes remains poorly defined. We aimed to evaluate national treatment trends for DCIS and to determine their impact on disease-specific (DSS) and overall survival (OS). METHODS: The Surveillance, Epidemiology, and End Results (SEER) registry was queried for patients diagnosed with DCIS from 1991 to 2010. Treatment pattern trends were analyzed using Cochran-Armitage trend test. Survival analyses were performed using inverse probability weights (IPW)-adjusted competing risk analyses for DSS and Cox proportional hazard regression for OS. All tests performed were two-sided. RESULTS: One hundred twenty-one thousand and eighty DCIS patients were identified. The greatest proportion of patients was treated with lumpectomy and radiation therapy (43.0%), followed by lumpectomy alone (26.5%) and unilateral (23.8%) or bilateral mastectomy (4.5%) with significant shifts over time. The rate of sentinel lymph node biopsy increased from 9.7% to 67.1% for mastectomy and from 1.4% to 17.8% for lumpectomy. Compared with mastectomy, OS was higher for lumpectomy with radiation (hazard ratio [HR] = 0.79, 95% confidence interval [CI] = 0.76 to 0.83, P < .001) and lower for lumpectomy alone (HR = 1.17, 95% CI = 1.13 to 1.23, P < .001). IPW-adjusted ten-year DSS was highest in lumpectomy with XRT (98.9%), followed by mastectomy (98.5%), and lumpectomy alone (98.4%). CONCLUSIONS: We identified substantial shifts in treatment patterns for DCIS from 1991 to 2010. When outcomes between locoregional treatment options were compared, we observed greater differences in OS than DSS, likely reflecting both a prevailing patient selection bias as well as clinically negligible differences in breast cancer outcomes between groups.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

December 2015

Volume

107

Issue

12

Start / End Page

djv263

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Survival Analysis
  • Sentinel Lymph Node Biopsy
  • SEER Program
  • Receptors, Progesterone
  • Receptors, Estrogen
  • Radiotherapy, Adjuvant
  • Proportional Hazards Models
  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Worni, M., Akushevich, I., Greenup, R., Sarma, D., Ryser, M. D., Myers, E. R., & Hwang, E. S. (2015). Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. J Natl Cancer Inst, 107(12), djv263. https://doi.org/10.1093/jnci/djv263
Worni, Mathias, Igor Akushevich, Rachel Greenup, Deba Sarma, Marc D. Ryser, Evan R. Myers, and E Shelley Hwang. “Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ.J Natl Cancer Inst 107, no. 12 (December 2015): djv263. https://doi.org/10.1093/jnci/djv263.
Worni M, Akushevich I, Greenup R, Sarma D, Ryser MD, Myers ER, et al. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. J Natl Cancer Inst. 2015 Dec;107(12):djv263.
Worni, Mathias, et al. “Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ.J Natl Cancer Inst, vol. 107, no. 12, Dec. 2015, p. djv263. Pubmed, doi:10.1093/jnci/djv263.
Worni M, Akushevich I, Greenup R, Sarma D, Ryser MD, Myers ER, Hwang ES. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. J Natl Cancer Inst. 2015 Dec;107(12):djv263.
Journal cover image

Published In

J Natl Cancer Inst

DOI

EISSN

1460-2105

Publication Date

December 2015

Volume

107

Issue

12

Start / End Page

djv263

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Survival Analysis
  • Sentinel Lymph Node Biopsy
  • SEER Program
  • Receptors, Progesterone
  • Receptors, Estrogen
  • Radiotherapy, Adjuvant
  • Proportional Hazards Models
  • Oncology & Carcinogenesis